血浆游离DNA浓度与转移性去势抵抗性前列腺癌紫杉类治疗结局:两项III期试验分析
基于FIRSTANA和PROSELICA两项III期试验的571例mCRPC患者,分析血浆cfDNA浓度与紫杉类化疗结局的关联。基线cfDNA较高与更短rPFS和OS独立相关,治疗早期cfDNA下降与PSA缓解相关,提示cfDNA可作为紫杉类治疗的预后生物标志物。
要点
- 基线cfDNA浓度较高与mCRPC患者紫杉类治疗后rPFS和OS更短独立相关。
- PSA缓解患者在前四个治疗周期中cfDNA浓度下降。
- cfDNA浓度变化与rPFS和OS相关,可能作为紫杉类反应的独立预后标志物。
核心结论
- cfDNA浓度变化与一线和二线紫杉类治疗患者的rPFS和OS相关,可能作为紫杉类反应的独立预后生物标志物。
研究设计与样本
- 前瞻性收集FIRSTANA和PROSELICA两项III期试验中571例mCRPC患者的血样进行cfDNA分析,共2502份样本。
- FIRSTANA患者接受多西他赛75mg/m2或卡巴他赛20或25mg/m2作为一线化疗,PROSELICA患者接受卡巴他赛20或25mg/m2作为二线化疗。
主要发现
- 基线log10 cfDNA浓度与已知预后因素相关,并与更短rPFS(HR=1.54;95%CI 1.15-2.08;p=0.004)和更短OS(HR=1.53;95%CI 1.18-1.97;p=0.001)相关。
- 多变量分析中,基线cfDNA浓度是一线和二线化疗中rPFS和OS的独立预后变量。
- PSA缓解患者在前四个治疗周期中log10 cfDNA浓度下降(每周期-0.03;95%CI -0.044至-0.009;p=0.003)。
关键数值与推荐
- 基线log10 cfDNA浓度与rPFS的HR=1.54(95%CI 1.15-2.08;p=0.004),与OS的HR=1.53(95%CI 1.18-1.97;p=0.001)。
- PSA缓解者前四个周期log10 cfDNA浓度每周期下降-0.03(95%CI -0.044至-0.009;p=0.003)。
临床怎么用
- 基线cfDNA浓度可用于识别侵袭性前列腺癌患者,辅助预后分层。
- 治疗早期cfDNA浓度下降可提示患者从紫杉类化疗中获益。
局限性
- 血样采集并非所有患者强制进行。
- 无法特异定量cfDNA中肿瘤来源的cfDNA比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as biomarkers of patient outcome following taxane chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Blood for cfDNA analyses was prospectively collected from 571 mCRPC patients participating in two phase III clinical trials, FIRSTANA (NCT01308567) and PROSELICA (NCT01308580). Patients received docetaxel (75mg/m2) or cabazitaxel (20 or 25mg/m2) as first-line chemotherapy (FIRSTANA), and cabazitaxel (20 or 25mg/m2) as second-line chemotherapy (PROSELICA). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations between cfDNA concentration and prostate-specific antigen (PSA) response were tested using logistic regression models. Survival was estimated using Kaplan-Meier methods for cfDNA concentration grouped by quartile. Cox proportional hazard models, within each study, tested for associations with radiological progression-free survival (rPFS) and overall survival (OS), with multivariable analyses adjusting for baseline prognostic variables. Two-stage individual patient meta-analysis combined results for cfDNA concentrations for both studies. RESULTS AND LIMITATIONS: In 2502 samples, baseline log10 cfDNA concentration correlated with known prognostic factors, shorter rPFS (hazard ratio [HR]=1.54; 95% confidence interval [CI]: 1.15-2.08; p=0.004), and shorter OS on taxane therapy (HR=1.53; 95% CI: 1.18-1.97; p=0.001). In multivariable analyses, baseline cfDNA concentration was an independent prognostic variable for rPFS and OS in both first- and second-line chemotherapy settings. Patients with a PSA response experienced a decline in log10 cfDNA concentrations during the first four cycles of treatment (per cycle -0.03; 95% CI: -0.044 to -0.009; p=0.003). Study limitations included the fact that blood sample collection was not mandated for all patients and the inability to specifically quantitate tumour-derived cfDNA fraction in cfDNA. CONCLUSIONS: We report that changes in cfDNA concentrations correlate with both rPFS and OS in patients receiving first- and second-line taxane therapy, and may serve as independent prognostic biomarkers of response to taxanes. PATIENT SUMMARY: In the past decade, several new therapies have been introduced for men diagnosed with metastatic prostate cancer. Although metastatic prostate cancer remains incurable, these novel agents have extended patient survival and improved their quality of life in comparison with the last decade. To further optimise treatment allocation and individualise patient care, better tests (biomarkers) are needed to guide the delivery of improved and more precise care. In this report, we assessed cfDNA in over 2500 blood samples from men with prostate cancer who were recruited to two separate international studies and received taxane chemotherapy. We quantified the concentration of cfDNA fragments in blood plasma, which partly originates from tumour. We identified that higher concentrations of circulating cfDNA fragments, prior to starting taxane chemotherapy, can be used to identify patients with aggressive prostate cancer. A decline in cfDNA concentration during the first 3-9 wk after initiation of taxane therapy was seen in patients deriving benefit from taxane chemotherapy. These results identified circulating cfDNA as a new biomarker of aggressive disease in metastatic prostate cancer and imply that the study of cfDNA has clinical utility, supporting further efforts to develop blood-based tests on this circulating tumour-derived DNA.
引用
- Mehra N, Dolling D, Sumanasuriya S, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. 2018. PMID: 29500065. doi:10.1016/j.eururo.2018.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。